Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NIOX GroupCSSPF 77 Days Sales Outstanding is 39.91 as of Dec. 2025, which is 4% above its 10-year median of 38.33. GuruFocus rates CSSPF with a GF Score™ of 77/100 and a GF Value™ of $1.21 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 811 Medical Devices & Instruments companies, NIOX Group ranks better than 87.18% on this metric.
NIOX Group's average Accounts Receivable for the
six
months ended in Dec. 2025 was $6.88 Mil. NIOX Group's Revenue for the
six
months ended in Dec. 2025 was $31.46 Mil.
Hence, NIOX Group's Days Sales Outstanding for the
six
months ended in Dec. 2025 was 39.91.
The historical rank and industry rank for NIOX Group's Days Sales Outstanding or its related term are showing as below:
CSSPF'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 27.96 Med: 38.33 Max: 217.63
Current: 36.97
During the past 13 years, NIOX Group's highest Days Sales Outstanding was 217.63. The lowest was 27.96. And the median was 38.33.
CSSPF's Days Sales Outstanding is ranked better than 87.18% of 811
companies
in the Medical Devices & Instruments industry
Industry Median: 66.24
vs CSSPF: 36.97
NIOX Group's Days Sales Outstanding
declined
from Dec. 2024 (40.49) to Dec. 2025 (39.91).
NIOX Group (OTCPK:CSSPF) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
NIOX Group Days Sales Outstanding Related Terms
NIOX Group Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for NIOX Group's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSSPF vs ABT, SYK, MDT: Days Sales Outstanding Comparison
For the Medical Devices subindustry, NIOX Group's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NIOX Group Days Sales Outstanding vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NIOX Group's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where NIOX Group's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NIOX Group (CSSPF) has a Days Sales Outstanding of 39.91 as of Dec. 2025. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on NIOX Group and its competitors. This is near median its historical median of 38.33. Over the past decade, NIOX Group's Days Sales Outstanding has ranged from 27.96 to 217.63. According to the industry distribution chart, NIOX Group ranks #104 out of 811 companies in the Medical Devices & Instruments industry, placing it in the top 12.8%.
Is NIOX Group's Days Sales Outstanding too high?
NIOX Group's current Days Sales Outstanding of 39.91 is near median its 10-year median of 38.33. Over the past 10 years, this metric has ranged from a low of 27.96 to a high of 217.63. The Medical Devices & Instruments industry median Days Sales Outstanding is 66.24. NIOX Group's value of 39.91 is 39.7% below this industry median. Based on the distribution chart, NIOX Group ranks #104 out of 811 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, NIOX Group has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does NIOX Group's Days Sales Outstanding compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, NIOX Group ranks #104 out of 811 companies for Days Sales Outstanding. This places NIOX Group in the top 13% of its industry — outperforming the majority of peers. The industry median Days Sales Outstanding is 66.24. NIOX Group's value of 39.91 is 39.7% below this benchmark. Historically, NIOX Group's own Days Sales Outstanding has ranged from 27.96 to 217.63 over the past decade. While the company's 10-year median is 38.33 vs. the industry median of 66.24, NIOX Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Devices & Instruments company?
The median Days Sales Outstanding among Medical Devices & Instruments companies is 66.24, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NIOX Group's current Days Sales Outstanding of 39.91 is 39.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on NIOX Group and its competitors. For the Medical Devices & Instruments industry, the median Days Sales Outstanding is 66.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NIOX Group's current Days Sales Outstanding is 39.91, which is near median its own 10-year median of 38.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NIOX Group stock overvalued right now?
Based on GuruFocus' analysis, NIOX Group (CSSPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $1.21, compared to a current price of $0.75 — trading 38% below its estimated fair value. The current Days Sales Outstanding is 39.91, which is near median its 10-year median of 38.33 and 39.7% below the Medical Devices & Instruments industry median of 66.24. NIOX Group's overall GF Score™ is 77/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For NIOX Group (CSSPF), the current Days Sales Outstanding is 39.91 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NIOX Group (CSSPF) Overvalued in 2026?
Based on GuruFocus' analysis, NIOX Group stock appears to be undervalued.
The current stock price of $0.75 is trading 38% below its estimated GF Value™ of $1.21.
GuruFocus considers NIOX Group to be Significantly Undervalued.
Key valuation signals for CSSPF:
Days Sales Outstanding: 39.91 (near median its 10-year median of 38.33)
GF Value™: $1.21 vs. price of $0.75 (38% below fair value)
Industry Position: 39.7% below the Medical Devices & Instruments median (#104 of 811)
No single metric tells the full story. See the CSSPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NIOX Group PLC is engaged in improving the diagnosis, monitoring and management of both asthma and COPD by providing greater patient access to FeNO testing. The company is engaged in the design, development, and commercialization of medical devices for the measurement of FeNO, a precise biomarker for type 2 inflammation which is present in asthma and COPD. Its device, NIOX VERO, is increasingly recognised by healthcare professionals as an important tool to improve the diagnosis, monitoring and management of asthma and COPD. It operates in single segment of NIOX relates to the portfolio of products used to improve asthma diagnosis, monitoring and management by measuring fractional exhaled nitric oxide (FeNO).
77GF Score
Get the complete analysis for CSSPF
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSSPF has been successfully added to your 
